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Abstract
The dopamine hypothesis is the longest standing pathoaetiologi cal theory of 
schizophrenia. As it was initially based on indirect evidence and findings in patients 
with established schizophrenia it was unclear what role dopamine played in the onset 
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of the disorder. However, recent studies in people at risk of schizophrenia have found 
elevated striatal dopamine synthesis capacity, and increased dopamine release to 
stress. Furthermore, striatal dopamine changes have been linked to altered cortical 
function during cognitive tasks, in-line with preclinical evidence that a circuit involving 
cortical projections to the striatum and midbrain may underlie the striatal dopamine 
changes. Other studies have shown that a number of environmental risk factors for 
schizophrenia, such as social isolation and childhood trauma, also impact on 
presynaptic dopaminergic function. 
Advances in preclinical work and genetics have begun to unravel the molecular 
architecture linking dopamine, psychosis and psychosocial stress. Included among 
the many genes associated with risk of schizophrenia, are the gene encoding the 
DRD2 receptor and those involved in the up-stream regulation of dopaminergic 
synthesis, through glutamatergic and gamma-aminobutyric acid (GABA)-ergic 
pathways. A number of these pathways are also linked to the stress response. We 
review these new lines of evidence and present a model of how genes and 
environmental factors may sensitise the dopamine system so that it is vulnerable to 
acute stress, leading to progressive dysregulation and the onset of psychosis. Finally, 
we consider the implications for rational drug development, in particular regionally 
selective dopaminergic modulation, and the potential of genetic factors to stratify 
patients.
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Introduction 
The dopamine hypothesis has been the leading pathoa etiological theory  of 
schizophrenia for over four decades (1–3). Our understanding of schizophrenia has 
progressed through advances in neuroimaging, epidemiology , and research in to the 
prodromal phase that predates the onset of the disorder in many patients. Meanwhile 
the role of genetic and environmental risk factors  for schizophrenia has  been 
clarified. Studies of how these risk factors impact on the dopamine system , coupled 
with longitudinal studies during the prodrome allow for a more refined understanding 
of what leads to the onset of psychosis. This review synthesizes the evidence on the 
nature of dopaminergic abnormalities in schizophrenia  and its prodrome, and how 
risk factors lead to illness, before considering the implications for treat ment and 
prevention.
The origins of the dopamine hypothesis
The origins of the dopamine hypothesis lie in  two lines of evidence. First, clinical 
studies establish ed that dopaminergic agonists , and stimulants could induce 
psychosis in healthy individuals, and worsen psychosis in patients with schizophrenia 
(4; 5) . Second, was the discovery that antipsychotic drugs affect the dopamine 
system (6). Later, the potency of antipsychotics was linked to their affinity for 
dopamine D2 receptors - linking molecular action to clinical phenotype (7).
Post-mortem studies provided the first  direct evidence for dopaminergic dysfunction 
in the brain and its anatomical localization. These  show ed elevated levels of 
dopamine, its metabolites , and its receptors in the striata of people with 
schizophrenia (8; 9) . However, the  studies were of patients who had received 
antipsychotics. Consequently, it was not clear if the dysfunction was linked to onset , 
or an end-stage effect of the disorder, or indeed a consequence of antipsychotics. 
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In vivo imaging of dopamine in schizophrenia
The development of positron emission tomography (PET) and single photon 
computed tomography (SPECT) specific radiotracers enabled the dopamine system 
to be studied in vivo with high molecular specificity (10).
Studies of the dopamine transporter ( DAT) (3; 11)  and  vesicular monoamine 
transporter (VMAT) (12; 13) availability in the striatum show no abnormality either in 
chronic patients or in drug na ïve first episode patients. Likewise, while meta-analysis 
has shown that there may be a small elevation in dopamine D2/3 receptor availability 
in schizophrenia, it is not reliably seen in antipsychotic-naive patients (3). 
Presynaptic  dopaminergic function can be indexed  using either radiolabelled l-
dihydroxyphenylalanine ( l-dopa), or  one can measure the change in radiotracer 
binding to D2/3 receptors following a challenge  designed to stimulate dopamine 
release.  A significant elevation was reported in a meta-analysis of presynaptic 
dopaminergic function using these techniques  (cohen ’s d=0.8) (3), and subsequent 
studies have re ported even larger effect sizes  (14–16). Furthermore baseline 
occupancy of D2/3 receptors by dopamine has also been found to be elevated, 
indicating higher synaptic dopamine levels at rest  (17; 18). Striatal dopamine release 
and baseline dopamine levels are closely correlated in schizophrenia  (19), 
suggesting that the same abnormality underlies both. 
While the striatum has received the greatest attention in PET studies, it has long 
been hypothesized that alterations in the dopamine system extend to additional brain 
regions (20).  Dopaminergic hypofunction in the dorsolateral prefrontal cortex  
(DLPFC) has been proposed to account for negative and cognitive symptoms. 
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Recently people with schizophrenia have been found to show reduced dopamine 
release in the DLPFC following amphetamine challenge, and this release was shown 
to correlate with DLPFC activation during a working memory task  (21). Meta-analysis 
of studies that have examined extra-striatal receptor densities indicate there are 
unlikely to be large differences in D2/3 receptors and transporters  in the regions 
studied, whilst the D1 findings are inconsistent, potentially due to the effects of prior 
antipsychotic treatment (22).
In vivo imaging of dopamine in people at clinical high risk of psychosis
The use of str uctured clinical assessments has made it  possible to identify cohorts 
with prodromal symptoms, in which the risk of transition to psychosis can be as high 
as 40%, though recent studies have reported lower rates  (23). Various studies have 
suggested that dopaminergic abnormalities exist in people at clinical high risk  (CHR) 
of psychosis. Antipsychotic treatment trials have demonstrated efficacy of dopamine 
blockade in reducing prodromal -type symptom severity  (24; 25) , and elevations in  
peripheral dopamine metabolites have been observed in CHR cohorts (26). However, 
these findings cannot tell us  directly about central dopaminergic dysfunction, in this 
respect imaging has been particularly useful. 
Three studies have examined D2/3 receptor density in CHR populations; all showing 
no differences  between group s (see table 1)  (27–29). In two studies this could 
conceivably have been due to increased synaptic dopamine masking a difference in 
receptor densities  (27; 28) . One study , however , addressed this with a dopamine 
depletion paradigm, and showed no significant differences (29).
Presynaptic dopaminergic function
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Initial research showed that dopamine synthesis capacity was raised in CHR 
individuals (30), and positively associated with the severity of prodromal -type 
symptoms (see table 1). This has subsequently been replicated (31), and found to be 
specific to prodromal individuals who progress to psychosis  (32). Furthermore , re-
scanning subjects as they developed psychosis showed that dopamine  synthesis 
capacity increases further with the development of acute psychosis (33). Additionally, 
greater dopamine release  was found following psychological stress in CHR 
individuals compared to controls (15). The dopamine dysfunction was localized to the 
dorsal striatum, particularly areas functionally linked with the prefrontal cortex  (PFC), 
and this was associated with altered function in frontal and temporal cortical regions  
(34; 35) . However, in contrast to findings in schizophrenia (17–19), dopamine 
depletion did not reveal differences in baseline synaptic levels of dopamine between 
at risk individuals and healthy controls, although at risk individuals reported 
symptomatic improvement following depletion (29). These findings indicate that whilst 
dopaminergic functioning is already dysregulated in those prodromal people who later 
progress to schizophrenia, it is not as marked as in patients with the disorder , and 
there is further dysregulation from the prodrome to psychosis.
Psychosocial stress and schizophrenia
In addition to genetic factors, neurodevelopmental hazards  (36) and cannabis use  
(37); chronic psychosocial stressors including childhood adversity  (38), 
migration/ethnic minority status  (39), and urbanicity (40), have become accepted as 
increasing the risk of schizophrenia. Furthermore , acute stress plays a role in  
triggering psychotic symptoms  (41; 42), and impaired stress tolerance is associated 
with prodromal symptoms (43). 
The effects of psychosocial stress on dopamine 
6
Animal studies  consistently show that acute stressors (psychosocial  and physical) 
lead to cortical dopamine release, and that this dampens striatal dopamine release  
(53; 54) . Dopaminergic inhibition of cortical glutamatergic neurons projecting to the 
striatum and midbrain is one pathway that potentially accounts for th is (see figure 1)   
(55). The effects of chronic stress on the dopamine system vary by brain region and 
depend on the nature of the stress . In animals exposed to chronic stress, baseline 
levels of frontal dopaminergic activity are reduced, but responses to acute stress are 
elevated (56; 57). With regard to the mesostriatal system, some studies  suggest that 
chronic stress reduce s dopaminergic response s to later activating stimuli  (58–60), 
while others  show increased release in response to  subsequent  amphetamine  (61; 
62). It seems that prior exposure to chronic or inescapable stressors may down 
regulate the system, while intermittent and escapable stress is more likely to have a 
sensitising effect (60; 63).
Studies of CHR individuals, individuals with schizophrenia  and first degree relatives 
have shown that they  produce a greater peripheral homovanillic acid  response to 
stress (26; 64; 65) . Two healthy volunteer PET studies demonstrated more 
widespread cortical displacement of a D2/3 radiotracer during a stress task relative to 
a control task  (66; 67) (see table 3) . In one of these a positive correlation between 
childhood adversity and extent of cortical dopamine release was observed  (68). The 
authors interpret this as potentially a resilience promoting mechanism. A study of first 
degree relatives of individuals with schizophrenia showed less widespread cortical 
dopaminergic response to stress relative to healthy controls  (69), and this was 
related to subjective stress and increased psychotic-like reactions to stress  (70).
Blunted cortical release of dopamine to amphetamine has been found in 
schizophrenia (21). However, a study of individuals with schizophrenia found no 
difference in the regional extent of cortical dopaminergic response to stress 
7
compared to controls , although the participants in this study had low symptom 
severity (71).
In the striatum , greater striatal dopamine release in response to acute social stress 
has been observed both in individuals at risk for psychosis (15; 76) and those with 
schizophrenia (28).  Additionally, greater dopamine synthesis capacity  (72), and 
release ( in response to stress (73) and amphetamine (74)) has been found in 
individuals exposed to childhood adversity.  Greater dopamine release to 
amphetamine was also  seen in people  exposed to social isolation by virtue of 
hearing impairment (75).  
Molecular mechanisms linking dopamine, stress and psychosis
A diathesis-stress model of schizophrenia proposes that the illness develops due to 
stress exposure acting on a pre-existing vulnerability (secondary to genetic factors or 
early environmental insults) (77; 78). However, the molecular architecture underlying 
this relationship remains unclear. Genetic studies provide a means of identifying 
potential molecular mechanisms that underlie the disorder without the risk of 
confounding by treatment or other factors. 
The genetics of schizophrenia and the dopamine system
Amongst the 108 loci associated with schizophrenia in the largest scale GWAS to 
date, one was for the dopamine receptor 2 (D2)  (79). Furthermore a recent 
systematic pathway analysis of the Psychiatric Genetics Consortium ’s enlarged 
sample (PGC2) GWAS findings identified the top pathway for genes associated with 
schizophrenia as being that for dopamine rgic synapse  (80)  (Holmans P, personal 
communication). However, this is a large set of genes , which includes many involved 
more widely in neurotransmission and signalling , that impinge indirectly on 
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dopaminergic transmission. For example both AMPA and NMDA receptor subtypes 
are included. A more recent analysis of the PGC2 GWAS data focussed on a set of 
11 genes more directly related to dopamine  synthesis, metabolism and 
neurotransmission (81). This confirmed the association with SNPs in the vicinity of 
DRD2, but found no evidence for enrichment in the other genes , or in the set as a 
whole.  While these results  do not add further support to the hypothesis that direct 
effects on dopaminergic neurotransmission partially mediate genetic susceptibility to 
schizophrenia, they do not exclude a role for rare variants in core dopaminergic 
genes, or other mutational mechanisms such as repeat sequences that are poorly 
tagged in GWAS studies. It remains to be determined whether there is enrichment of 
genetic signal in other restricted gene sets relating to dopaminergic function , such as 
signal transduction and post-synaptic signalling.  It is also possible that dopaminergic 
genes play a more prominent role in clinical subsets of schizophrenia or in cases 
defined on the basis of drug response.  
The finding from PGC2 that SNPs at the DRD2 locus are associated with 
schizophrenia is of great potential relevance to understanding the role of 
dopaminergic neurotransmission in the disorder , and to identifying upstream and 
downstream mechanisms . However, it is possible that the associated SNP(s) are 
modulating the function of another gene either in cis or trans rather than DRD2 itself. 
There is thus a pressing need to determine how, where and at what developmental 
stage(s) this association impacts mechanistically on gene function . As well as 
confirming an aetiological role for dopamine dysfunction t his might be expected to 
provide important new insights into the nature of dopamine system dysfunction in the 
disorder.
Genes involved in dopaminergic neurotransmission downstream of the synapse have 
9
also been linked to an increased risk of schizophrenia. Post-synaptic dopamine 
neurotransmission includes kinases such as  the serine-threonine kinase Akt. Akt3 
was associated with schizophrenia in the GWAS described above  (79), while Akt1 
has been linked to schizophrenia in other studies  (82; 83) . Functional changes to 
post-synaptic signal transduction could conceivably alter regulatory feedback onto 
presynaptic dopaminergic neurons (84). 
The genetics of psychosocial stress and the dopamine system
Gene-environment studies using epidemiological approaches have demonstrated 
interactions between genetic and psychosocial risk factors for schizophrenia (85–87). 
The importance of environmental effects may explain why the dopamine imaging 
evidence is inconsistent in people who may carry genetic risk for schizophrenia, such 
as relatives of people with schizophrenia , both in terms of dopamine synthesis 
capacity (88; 89) , and D1  (90) and D2  (91; 92)  recept or availability (see table 2). 
Below we discuss genes that may mediate the relationship between stress exposure, 
dopaminergic functioning, and psychosis.
Catechol-O-methyltransferase (COMT, a major dopamine catabolic enzymes) was 
implicated in early candidate gene studies, and is located within one of the strongest 
genetic risk factors for schizophrenia, a 1.5-3 Mb deletion at 22q.11.2 . (93) COMT 
contains a functional polymorphism involving a valine (Val) to methionine (Met)  
substitution. The functional consequences of variation at this locus have been widely 
studied, but it should be born in mind that there was no evidence for association of 
the Val/Met variant with schizophrenia in the PGC2 (95). The Met allele is associated 
with reduced catabolic activity , and is linked to greater tonic and reduced phasic  
striatal dopaminergic transmission (96). In the cortex , a PET study investigating D1 
receptor density suggested that the Val allele was associated with  lower levels of 
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baseline dopamine( 99) (although no association was observed in a study of cortical 
D2 receptors)  (98). A study examining stress  induced cortical dopamine release 
suggested the Met allele was associated with reduced release (and a greater 
subjective stress response) (99). 
Stress induced catecholamine release can impair working memory  (100). During 
acute stress, Met homozygotes show impairment s in working memory  performance 
and reduced PFC activation, while Val carriers show the opposite  effects (101; 102). 
This has been interpr eted in terms of the inverted-U relationship between dopamine 
levels and cognitive function  – the greater level of dopaminergic function at baseline 
in Met carriers means an increase impairs performance ; whereas i n the case of the 
Val allele, the increase is beneficial.
In terms of chronic stress, Met homozygosity has been associated with a negative 
relationship between the number of stressful life events and hippocampal volume, 
while the opposite relationship is seen for Val homozgosity (103). In Val homozygotes 
increased lifetime stress was found to correlate with reduced  methylation which in 
turn correlated with poorer working memory performance  (104). The Val allele has a 
methylation site absent on the Met allele, it may be that increased methylation in Val 
homozygotes, leads to reduced gene expression, leading to individuals ’ COMT 
having activity similar to a Met carrier.  
Similarly to COMT, brain-derived neurotrophic factor (BDNF) has a Val/Met functional 
polymorphism. A  PET study of BDNF polymorphisms showed that Met carriers had 
greater striatal dopamine release in the context of a pain stressor  (105).  Consistent 
with this finding, the Met allele has been associated with increased stress induced 
paranoia in healthy individuals (106).
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The expression and functioning of DRD2 is affected by both genetic polymorphisms 
and environmental factors. In a healthy volunteer study , heterozygotes for a DRD2 
SNP showed greater stress induced striatal dopamine release compared to 
homozygotes (107). An animal study showed increased D2 receptor density in the 
nucleus accumbens following early life maternal deprivation, but only in 
heterozygotes for a separate DRD2 polymorphism (108).
In contrast to studies of synaptic and post-synaptic dopamine genes, there have 
been fewer for presynaptic genes, such as those for synthetic enzymes and proteins 
regulating presynaptic storage of dopamine. Whilst the few published  studies  are 
inconsistent (109–111), this is an area that warrants investigation given the imaging 
findings. Disrupted In Schizophrenia (DISC1) is involved in a pathway that regulates 
presynaptic dopaminergic function, is one of the best studied loci linked to an 
increased risk of schizophrenia  (112), and displays abnormal expression in induced 
pluripotent stem cells  (IPSCs)  from individuals with schizophrenia (113).  Animal 
models have demonstrated that alterations in DISC1 can lead to both impaired 
development of mesocortical dopaminergic neurons, and increased amphetamine 
induced striatal dopamine release (114). Adolescent isolation stress has been shown 
to lead to behavioural abnormalities only in mice with DISC1 mutations , secondary to 
glucocorticoid mediated changes to the functioning of mesocortical dopaminergic 
pathways (115). DISC1 is also involved in anchoring phosphodiesterase 4A (PDE4A) 
next to the spine apparatus  (116). The gene coding for PDE4A has also been linked 
to schizophrenia  (117), and both DISC and PDE4A together modulate  modulate  
stress signalling pathways. Impairment of DISC1 reduces its ability to anchor PDE4A 
and this in turn leads to a disinhibition of the stress response and accompanying PFC 
impairment (122). 
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The relationship between dopamine and other neurotransmitters
DISC1 is also involved in glutamatergic neurotransmission  (112). Furthermore, both 
GWAS and copy number variant (CNV) studies have implicated other genes involved 
in glutamatergic neurotransmission , including N-Methyl-D-Aspartate (NMDA) and 
other glutamatergic receptors  (123). There is evidence that NMDA hypofunction 
disrupts the inhibitory/excitatory equilibrium at interneurons and thereby leads to 
increased dopamine release (see figure 1 and Abi-Dargham et al also in this issue)  
(124–126). Neurons derived from IPSCs from patients with schizophrenia show 
greater basal and activity dependent dopamine secretion  (127), as well as reduced 
glutamate receptor and altered DISC1 expression  (113). Glutamatergic 
neurotransmission is also mediates the effects of both  a cute and chronic stress 
(128).
Recent evidence from over 11,000 patients with schizophrenia and 16,000 controls 
has also  shown an enrichment of CNVs involving glutamatergic and GABAergic 
systems (129). These systems have excitatory and inhibitory effects respectively on 
dopaminergic function , suggesting that the genetic variants in these systems may 
alter the regulation of dopamine in schizophrenia. Thus it is plausible that a number 
of the genetic risk variants in upstream pathways modulate dopamine function.  
Future studies must first clarify the molecular pathways, and links between the 
genetic variants and effects on glutamatergic and GABAergic neuronal function, 
before the link to down-stream dopaminergic effects can be tested.
Integrating the imaging, stress and genetic findings
Collectively the imaging findings identify  increased striatal presynaptic synthesis and 
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release of dopamine , as the major locus of dopamine rgic dysfunction in 
schizophrenia. Furthermore, it appears this dysfunction is also present in the 
prodrome, and link ed to the clinical development of the disorder. This suggests that 
presynaptic striatal dopamine dysfunction plays a causal role i n the development of 
psychosis.
The genetic findings have not implicated genes directly involved in determining 
dopamine synthesis or release , but instead point to up-stream and down-stream 
pathways linked to the dopamine system. A number of the genetic risk factors 
converge on up-stream pathways, particularly those involving glutamatergic systems. 
As glutamatergic projections to the striatum and midbrain regulate presynaptic 
dopaminergic function , genetic variants affecting glutamatergic function  could alter 
the regulation of dopaminergic function . The net effect of this may be  to reduce the 
homeostatic control of midbrain dopamine neurons, making them more vulnerable to 
sensitisation by the  socio-developmental risk factors described above. In addition, a 
number of other genetic risk factors impact on dopamine receptors and post-synaptic 
signal transduction pathways , to modulate post-synaptic dopaminergic 
neurotransmission. The net effect of this may be to increase the sensitivity of the 
medium spiny neurons in the striatum to dopamine. This suggests that the genetic 
risk factors for schizophrenia may pl ay two roles: the up-stream factors render  the 
dopamine neurons vulnerable to dysregula tion, whilst the down-stream factors  
amplify the effects of dysregulation.
We have also discussed the  effect of stress on the  cortico-striatal dopamine system, 
and how genetic and environmental influences moderate this . Recent studies in 
patients with schizophrenia and their relatives show blunted cortical dopamine 
release to a challenge. This is likely to reduce the inhibition of meso-striatal dopamine 
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release, and result in augmented  stress induced  striatal release of dopamine . The 
preclinical findings suggest that this involves glutamatergic projections to the striatum 
and midbrain acting on GABAergic interneurons, both of which may hypofunctional 
due to genetic risk variants affecting glutamatergic and GABAergic receptors linked 
to schizophrenia. Thus blunted cortical dopaminergic release to stress coupled with 
impaired glutamatergic regulation of dopamine neurons may act on a sensitized 
mesostriatal dopamine system to result in increased striatal dopamine dysfunction  
(see figure 2). 
Treatment Implications
Current pharmacological treatments for schizophrenia primarily operate as post -
synaptic D2/3 receptor antagonists (130). Whilst these bring symptomatic relief , they 
do not target the underlying pathophysiology  - even patients who have responded to 
antipsychotics show elevated striatal dopamine synthesis capacity  (131). 
Furthermore, antipsychotics show limited effectiveness in targeting negative and 
cognitive symptoms. 
Given the evidence that cognitive symptoms are linked  to cortical hypofunction, 
including reduced cortical dopamine release, it is unsurprising that dopamine 
blockade does not help these symptoms. Furthermore, anti-dopaminergic blockade of 
ventral striatal regions may impair motivation and affective processing , and so 
worsen negative symptoms. A clear implication is that we need regionally selective 
treatments: dampening dopamine neurotransmission in the striatum, specifically the 
dorsal striatum where dopamine elevation is most marked, and augmenting it in the 
cortex. Animal studies suggest that some existing pharmacological agents  such as 
mirtazapine may be able  to selectively augment cortical dopamine transmission . 
Interestingly, mirtazapine is used as a treatment in stress related disorders (133), and 
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it may be  an effective adjunctive treatment for negative symptoms  in schizophrenia  
(134).
Up-stream and down-stream genetic factors may have implications for treatment. 
Putatively people with a high loading for up-stream genetic risk might show marked 
presynaptic dopamine dysfunction, whilst those with a high loading for post-synaptic 
risk might show minimal presynaptic dysfunction but would be highly sensitive to the 
effects of even small amounts of dopamine release. There is evidence that a sub-
group of individuals with schizophrenia and co-morbid substance dependence  (135) 
or cannabis-induced psychotic symptoms  (49) do not show increased dopamine 
synthesis or release, and that sensitivity to the psychotogenic effects of cannabis is 
linked to these down-stream genetic risk facto rs. Individuals predominantly affected 
by down-stream factors might be more sensitive to the side-effects of D2/3 receptor 
blockade (136), but might tolerate partial agonists better. 
Limitations
A number of the aspects of the model described await testing . It remains to be 
established if genetic and environmental factors interact to sensitiz e the dopamine 
system, if there is blunted cortical dopamine release in the prodrome, and if blunted 
cortical dopaminergic function leads to striatal hyperdopaminergia.  Moreover, whilst 
preclinical evidence support s the glutamatergic circuit regulating  dopamine , the 
specifics remain to be tested in humans and reverse causality is yet to be excluded.
A number of the COMT findings are difficult to integrate into the model.  There is no 
evidence from GWAS  supporting association with SNPs in COMT.  In healthy 
individuals, the Val allele is associated with increased social stress induced paranoia  
(106; 137) . This allele has also  been associated w ith greater symptom  severity in 
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individuals with psychotic disorders  (138; 139) . However, in individuals with a 
psychotic disorder , Met homozygotes demonstrate increased psychotic reactivity to 
stress (140; 141). This does not fit with a model where reduced Met activity would be 
protective for individuals with a psychotic disorder – where we propose a deficit of  
cortical dopamine. This inconsistency may be due to the precise nature of the 
stressors under examination , or potentially due to gene-gene-environment 
interactions.
Whilst glutamatergic and GABAergic alterations have been reported in  neuroimaging 
studies of schizophrenia (124; 142), and the prodrome  (143), the precise molecular 
abnormalities remain to be determined in vivo. The links between  glutamatergic 
dysregulation and dopaminergic signalling remain to be determined in schizophrenia  
(124), although there is some evidence of this in the prodrome (144). 
Conclusions
Altered presynaptic striatal dopamine synthesis and release  is consistently seen in 
schizophrenia. This is also seen  to a lesser degree in the prodrome , and becomes 
worse as  frank psychosis  manifests . Blunted c ortical dopamine release has now 
been demonstrated  in schizophrenia, and  there is increasing evidence that altered 
cortical function is linked to striatal dopamine hyperactivity  in people with prodromal 
symptoms, indicating a central role for cortico-striatal dysregulation. Furthermore, it is 
now possible to begin to understand how genetic and environmental risk factors may 
lead to striatal dopamine dysregulation by impairing the cortical regulation of midbrain 
dopamine neurons. However, the precise molecular mechanisms remain to be fully 
elucidated, and blunted cortical dopamine release has yet to be investigated in the 
prodrome. Nevertheless, half a century on from the initial formulations of the 
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dopamine hypothesis, it is  possible to see what  we need to do in order to rationally 
design medications that target the pathophysiology underlying the onset of the 
disorder to treat it, or indeed potentially prevent it.
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Table 1:  PET studies of the dopaminergic system in individuals at increased clinical risk of schizophrenia
↑: significantly higher in patient group; ↓: significantly lower level in patient group; -: no significant difference. [123I]IBZM: [123I](S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-
pyrrolidinyl)methyl]benzamide; [11C]-+-PHNO: [11C]-(+)-4-propyl-9-hydroxynaphthoxazine; [18F]- DOPA: 6-[18F]fluoro-L-Dihydroxyphenylalanine; DA: dopamine; MIST: Montreal Imaging Stress Task; D1, 
D2, D3: Dopamine receptor sub-type 1, 2 and 3 respectively; HC: healthy control; Scztyp: Schizotypal; UHR: Clincial high risk for psychosis. 
aSynthesis capacity increased only in subgroup that transitioned to psychosis (n=9). 
b MIST leads to significant decrease in tracer binding in subgroup characterised as ‘potential schizotype’ on the basis that subjects scored >1.95 SD on the negative subscale of Chapman schizotypy 
questionnaire.
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Study Population Radiotracer Study type Region Reported Findings (standard effect size) Additional findings
Bloemen et al. 
2013(29) 
14 CHR 
15 HV
[123I]IBZM
Dopamine               
depletion
Striatum
- 
Positive correlation between D2/3 
receptor occupancy by dopamine 
and positive CHR symptoms
Howes et al. 2009 (30)
24 CHR
12 HV
[18F]-DOPA
Dopamine 
synthesis capacity
Striatum  (0.75)
Howes et al. 
2011b(32) a
30 CHR 
29 HV
[18F]-DOPA
Dopamine 
synthesis capacity
Striatum (1.18)a
No change in CHR subjects who 
did not convert to psychosis
Mizrahi  et al. 2012(28)
12 CHR
12 HV
[11C]-+-PHNO
MIST induced 
dopamine release
Striatum (0.98)
Suridjan et al. 2013 
(27)
12 CHR
12 HV
[11C]-+-PHNO
D2high/D3 receptor 
availability
Striatum, thalamus, 
globus pallidus, 
substantia nigra
-
Abi-dargham  et al. 
2004(146)
13 Scztyp
13 HV
[123I]IBZM
Amphetamine 
induced dopamine 
release
Striatum  (0.93)
Soliman et al. 
2008(76)b
16 Scztyp
10 HV
[11C] raclopride
MIST  induced 
dopamine release
Ventral striatum
Study Population Phenotype Radiotracer Study type Region Reported
Change in genetic 
high risk group 
(standard effect 
Table 2:  PET studies of the dopaminergic system in individuals at increased genetic risk of schizophrenia
2DG: 2-Deoxy-D-glucose; DA: dopamine; DZ: Dizygotic; GHR: Genetic high risk; mPFC: Medial prefrontal cortex; MZ: monozygotic; STG: superior temporal gyrus.
Study Population Radiotracer Findings
Nagano-Saito 
et al., 2013 
(67)
 11 HV [18F]-Fallypride 
MIST
Stress induces displacement in dmPFC, vmPFC, PCG (15.87%), 
thalamus, L caudate, R putamen. No displacement observed in 
amygdala or ventral striatum
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size)
Brunelin et al. 
2010 (147)
8 GHR
10 HV
Siblings of patients 
with schizophrenia
[11C]raclopride
2DG induced 
dopamine release
Whole striatum.
GHR show greater asymmetry 
between L/R striatum. No 
differences in DA release in 
ventral striatum
↓
Huttunen  et al. 
2008 (89)
17 GHR
17 HV
1st degree relatives 
of patients with 
schizophrenia
[18F]-DOPA
Dopamine synthesis 
capacity
Caudate and putamen
No differences observed in 
ventral striatum
Shotbolt  et al. 
2011 (88)
6 GHR
20 HV
Co-twins of patients 
with schizophrenia
[18F]-DOPA
Dopamine synthesis 
capacity
Whole striatum -
Hirvonen et al. 
2005 (91)
6 MZ, 5 DZ, 
14 HV
Co-twins of patients 
with schizophrenia
[11C]raclopride
D2/3 receptor 
density
Caudate
No differences observed in 
putamen or thalamus
 (0.85)
Hirvonen et al. 
2006a (90)
6 MZ, 5 DZ, 
13  HV
Co-twins of patients 
with schizophrenia
[11C]SCH 
23390
D1 receptor density mPFC, STG and angular gyrus
Hirvonen et al. 
2006b (148)
6 MZ, 5 DZ, 
13  HV
Co-Twins of patients 
with schizophrenia
[11C]SCH 
23390, 
[11C]raclopride
D1:D2/3 ratio Caudate and putamen -
Lee et al. 2008 
(92)
11 GHR
11 HV
1st and 2nd degree  
relatives of patients 
with schizophrenia
[11C]raclopride
Striatal D2/3 
receptor density
Caudate and putamen.
GHR show ↓ asymmetry of 
receptor density in putamen
-
Lataster et al., 
2011 (66)
12 HV. [18F]-Fallypride 
MIST
Stress induces displacement in PFC. vmPFC DA release 
associated with subjectively rated stress. Extent of cortical release 
correlates with childhood adversity (68).
Hernaus et 
al., 2015b 
(71)
12 HV. 12 
NAPD
[18F]-Fallypride 
MIST
NAPD show non-significantly ↓ stress induced displacement in 
mPFC (d=0.31). 
Lataster et al., 
2014 (69)
11 HV. 14 
relatives
[18F]-Fallypride 
MIST
Relatives show ↓ proportion of voxels with displacement in mPFC 
(non significant. d=0.46). Relatives showed association between 
increased stress and decreased displacement (controls showed 
opposite).
Mizrahi et al., 
2012(28)
10 FEP
12 HV
12 CHR
PHNO
MIST
DA release greatest for FEP, then CHR (in assoc striatum). No 
increased release for HV. Whole –striatum - CHR>HV (d = 0.98). 
Limbic striatum (0.65).
Pruessner et 
al., 2004 (73)
5 Childhood 
hi-stress
5 Childhood 
low-stress
Raclopride
MIST
Childhood high stress group show significantly ventral striatal 
displacement compared to low stress group.
Oswald et al., 
2014 (74)
28 HV Raclopride
AMPH challenge
Past traumatic events and perceived stress associated with greater 
ventral striatal DA release
Egerton et al., 
2016 (72)
20 HV
47 CHR
[18F]-DOPA Physical and sexual abuse, and unstable family arrangements 
associated with increased dopamine synthesis capacity.
Table 3:  PET studies of the effects of acute and chronic stress on the dopaminergic system
CHR- Clinical High Risk; DA – dopamine; dmPFC – dorsomedial prefrontal cortex; FEP – First episode psychosis; HV – Healthy Volunteer; MIST – Montreal Imaging Stress Task; mPFC – medial prefrontal 
cortex; NAPD – non affective psychotic disorder; PCG – precentral gyrus; vmPFC – ventromedial prefrontal cortex
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Gene Function Relationship to dopamine, stress and schizophrenia
Akt1
Akt 3
Serine threonine kinases involved in post 
synaptic dopaminergic neurotransmission.
Changes in post synaptic signal transduction could lead to hypersensitivity to dopamine and alter 
presynaptic feedback. AKT1 has been linked to Scz in two studies (82; 83) . While AKT3 has been 
implicated in GWAS.
BDNF A neurotrophin that encourages the 
survival, growth and differentiation of 
neurons.
Met carriers show greater striatal DA release in the context of a pain stressor, and has been associate 
with greater stress induced paranoia.
COMT Catabolises dopamine (particularly cortical). 
Met allele associated with reduced catabolic 
activity.
Met allele has been linked to reduced stress induced cortical DA release. Chronic stress has been 
associated with greater reductions in hippocampal volume in  Met homozygotes.
DISC1 Participates in a wide range of cell 
functions. Involved in regulation presynaptic 
dopaminergic function. Also involved in 
anchoring PDE4A to spine apparatus.
Animal models demonstrate DIC1 alterations can impair development of mesocortical DA neurons and 
lead to increased AMPH induced striatal DA release. Adolescent stress has been shown to lead to 
behaviour abnormalities only in mice with DISC1 mutations.  Linked to Scz in multiple studies.
DRD2 Dopamine receptor 2 Changes in pre and postsynaptic receptor density or function may have marked effects on dopaminergic 
signalling. SNP has been associated with greater stress induced DA release. Animal study demonstrated 
a certain SNP is associated with increased D2R density in the nucleus accumbens following maternal 
deprivation. Locus associated in schizophrenia GWAS.
PDE4A Involved in in a variety of responses to 
extracellular signals.
Together with DISC1 involved in modulation of stress signalling pathways, impairment leads to 
disinhibition of the stress response and PFC impairment. Has been linked to schizophrenia.
Table 4: Genes related to dopaminergic functioning, schizophrenia and stress
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Figure 1. The regulation of mesostriatal dopaminergic function by 
cortical glutamatergic projections and GABAergic interneurons
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Figure 2. Model integrating genetic and environmental factors, dopaminergic 
dysregulation and the development of psychotic symptoms (DA=dopamine)


